RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MACERELLI M
Collezione AOU San Luigi di Orbassano

Items : 6

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1?50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. in Journal for immunotherapy of cancer / J Immunother Cancer. 2025 Feb 4;13(2):e010674. doi: 10.1136/jitc-2024-010674.

2025
AOU San Luigi di Orbassano
AOU Novara

Wakelee H; Garassino M; Peters S; Takada K; Naqash AR; Torri V; Hejleh TA; Ferrara R; Aerts JGJV; Aboubakar Nana F; Dingemans AM; Biello F; Rogado J; Moliner L; Beninato T; Lo Russo G; Servetto A; Mezquita L; Gorría T; Minuti G; Bennati C; Tonini G; Cortinovis DL; Agustoni F; Majem M; Baena J; Macerelli M; Monnet I; O'Reilly D; et alii...

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. in Journal of hematology & oncology / J Hematol Oncol. 2022 Jan 21;15(1):9. doi: 10.1186/s13045-022-01226-2.

2022
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Russo A; Porzio G; Tiseo M; Russano M; Ficorella C; Addeo A; Banna GL; Friedlaender A; Spinelli GP; Metro G; Migliorino MR; Passiglia F; Ricciardi S; Zoratto F; Pecci F; Di Marino P; Mansueto G; De Tursi M; Tuzi A; Gori S; Della Gravara L; Macerelli M; Rastelli F; Chiari R; Gelibter A; Marchetti P; Antonuzzo L; Mazzoni F; et alii...

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. in Journal for immunotherapy of cancer / J Immunother Cancer. 2021 Apr;9(4):e002421. doi: 10.1136/jitc-2021-002421.

2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Ficorella C; Porzio G; Cannita K; Addeo A; Banna GL; Friedlaender A; Spinelli GP; Russo A; Adamo V; Metro G; Bironzo P; Passiglia F; Ricciardi S; Migliorino MR; Landi L; Minuti G; Tuzi A; Bordi P; Russano M; Cantini L; Santini D; Citarella F; Zoratto F; Filetti M; Mansueto G; Di Marino P; Grassadonia A; Inno A; et alii...

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ? 50% and Their Relationship With Clinical Outcomes. in Clinical lung cancer / Clin Lung Cancer. 2020 Nov;21(6):498-508.e2. doi: 10.1016/j.cllc.2020.06.010. Epub 2020 Jun 21.

2020
AOU San Luigi di Orbassano

Cortellini A; Friedlaender A; Banna GL; Porzio G; Bersanelli M; Cappuzzo F; Aerts JGJV; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Berardi R; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Inno A; Di Marino P; Mansueto G; Zoratto F; et alii...

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ??50. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221. doi: 10.1007/s00262-020-02613-9. Epub 2020 May

2020
AOU San Luigi di Orbassano

Cortellini A; Tiseo M; Banna GL; Cappuzzo F; Aerts JGJV; Barbieri F; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Santini D; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; et alii...

Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial). in Therapeutic advances in medical oncology / Ther Adv Med Oncol. 2020 Jul 20;12:1758835920915983. doi: 10.1177/1758835920915983. eCollection 2020

2020
AOU San Luigi di Orbassano

Gelsomino F; Lamberti G; Tiseo M; Rocco D; Pasello G; Cecere FL; Chella A; Grilli G; Mandruzzato M; Tognetto M; Garassino MC; Macerelli M; Novello S; Roila F; Colantonio I; Grossi F; Fiorentino M; Ardizzoni A;